http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004092592-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2002-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb8192651b176ef80d051ca05fc3e96c |
| publicationDate | 2004-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2004092592-A1 |
| titleOfInvention | Stabilized L-Arginine platelet aggregation inhibitory compositions and processes for making same |
| abstract | Linking Magnesium ions to Nitric Oxide precursor L-Arginine, chemically 2-amino-5-guanidino valeric acid, with a platelet aggregation inhibitor compound such as, but not limited to acetylsalicylic acid or clopidogrel bisulfate, unexpectedly results in a pharmaceutically stabilized compositions with extended shelf life to be taken orally to provide gradual release vasodilatory and anti-platelet aggregation pharmacological activity with reduced potential for producing gastrointestinal lesions. L-Arginine releases ADNO (Arginine derived Nitric Oxide) in the coronary artery epithelium as EDRF (endothelium dependent relaxing factor) to dilate the arteries to promote blood flow to the myocardium, and the platelet aggregation inhibitor such acetylsalicylic acid or clopidogrel and others of this class of drugs inhibits or antagonizes the aggregation adhesion of platelets in the blood stream. Aggregated or clumped blood platelets contribute to arterial stenosis due to formation of atherosclerotic plaques that occlude coronary and other circulatory arteries. In addition to coronary arteries, atherosclerotic plaques can occlude and stenose carotid arteries and femoral arteries due to aggregated or clumped blood platelets, and the subject of this patent discovery will also be of cardiovascular health benefit respectively in preventing carotid cerebrovascular accidents and femoral artery leg circulation disease. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009532462-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010145053-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007113857-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007113857-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006228396-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108210927-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8445536-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1714650-A1 |
| priorityDate | 2002-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.